e-learning
resources
Munich 2014
Tuesday, 09.09.2014
Innovative technology and techniques in respiratory function
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
LATE-BREAKING ABSTRACT: Effect of inhalation profiles and throat geometries on predicted lung deposition of budesonide and formoterol (BF) when inhaled through two different devices
H. Chrystyn, G. Safioti, H. Keegstra, G. Gopalan (Huddersfield, United Kingdom; Helsingborg, Sweden; Haarlem, Netherlands; Malvern, United States Of America)
Source:
International Congress 2014 – Innovative technology and techniques in respiratory function
Session:
Innovative technology and techniques in respiratory function
Session type:
Thematic Poster Session
Number:
4258
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Chrystyn, G. Safioti, H. Keegstra, G. Gopalan (Huddersfield, United Kingdom; Helsingborg, Sweden; Haarlem, Netherlands; Malvern, United States Of America). LATE-BREAKING ABSTRACT: Effect of inhalation profiles and throat geometries on predicted lung deposition of budesonide and formoterol (BF) when inhaled through two different devices. Eur Respir J 2014; 44: Suppl. 58, 4258
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
In vitro lung deposition of fluticasone propionate/formoterol (FP/FORM) pressurized metered dose inhaler (pMDI) with different inhalation profiles
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Effects of extra fine formoterol or coarse particle salmeterol on impulse oscillometry (IOS) in corticosteroid treated persistent asthmatics
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
In-vitro emitted dose characteristics of combination budesonide / formoterol tubuhaler using patient inhalation profiles
Source: International Congress 2015 – Lung function: waiting to exhale...
Year: 2015
Extent of inhaled drug deposition at variable inhaler inclination angles and airway geometries: An in-vivo study from a novel computational fluid dynamics model
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
The effect of inhalation duration on lung deposition with a pressurized metered-dose inhaler (pMDI)
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Are extra-fine particles from dry powder inhalers likely to improve lung deposition?
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Lung deposition of extrafine inhaled corticosteroid (ICS)-containing fixed combinations drug in COPD patients using Functional Respiratory Imaging (FRI).
Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies
Year: 2018
Effect of interval between actuations of albuterol HFA inhalers on their aerosol characteristics
Source: International Congress 2016 – Paediatric asthma: recurrent, persistent, or severe obstruction and lung function techniques
Year: 2016
Effect of inhaled vilanterol trifenatate/fluticasone furoate on breathing pattern, dyspnea and respiratory muscle function in severe COPD
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014
In vitro
analysis of two formulations of fluticasone/ salmeterol pMDI for delivered dose uniformity and aerodynamic particle size distribution
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014
B2-adrenoceptor genotype16 influences airway calibre but not hyperresponsiveness in asthmatics using regular B2-agonist in addition to inhaled corticosteroids
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
LATE-BREAKING ABSTRACT: Structured light plethysmography to evaluate the effects of acute bronchodilation during tidal breathing in COPD patients
Source: International Congress 2014 – Innovative technology and techniques in respiratory function
Year: 2014
Study design supporting the effectiveness of inhaled extra-fine beclomethasone/formoterol at the level of small airways of asthmatics
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013
The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Lung deposition and distribution of inhaled extra fine beclomethasone dipropionate / formoterol fumarate /glycopyrronium bromide (BDP/FF/GB) in subjects with and without airflow obstruction.
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021
Lung deposition of extrafine vs non-extrafine triple therapies in patients with COPD using Functional Respiratory Imaging (FRI).
Source: International Congress 2019 – Imaging in respiratory disease: novel technologies in 2019
Year: 2019
Lung deposition analysis of two formulations of fluticasone/salmeterol HFA pMDI in stable asthma patients
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Late Breaking Abstract - Impact of eosinophil levels on lung function and exacerbation benefits with co-suspension delivery technology budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) in COPD (KRONOS study subgroup analysis)
Source: International Congress 2018 – Integrated care and non-pharmacological management of COPD
Year: 2018
Bronchodilator effect of high strength extrafine BDP/formoterol delivered via NEXThaler® in asthmatics
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Effects of treatment and withdrawal with inhaled beclomethasone/formoterol on electronic nose and NMR metabolomic breathprints in patients with COPD
Source: International Congress 2016 – Airway biomarkers
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept